Table 3.
Outcome | % change* | Lower 95% CI | Upper 95% CI | Sample size | |
---|---|---|---|---|---|
Full analysis | hsCRP | 5.8% | −36.6% | 76.5% | 23 |
IL-6 | 1.2% | −20.5% | 29.0% | ||
TNFRII | 3.3% | −3.0% | 9.9% | ||
Remove homes with least PNC reduction | hsCRP | 15.6% | −43.6% | 137.0% | 18** |
IL-6 | 3.6% | −19.9 | 34.1% | ||
TNFRII | 5.8% | −2.3% | 14.6% | ||
Remove homes with largest number of indoor spikes | hsCRP | −8.9% | −37.9% | 33.7% | 18** |
IL-6 | 0.3% | −25.8% | 35.5% | ||
TNFRII | 2.0% | −3.8% | 8.3% |
Adjusted for baseline; percent change is positive for higher blood biomarkers during HEPA.
The subgroup analyses are not the same set of participants, but instead the 18 participants with the largest PNC reduction and the fewest spikes respectively (see Table 2).